查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1586051

癌症免疫治療市場：按產品、功能和最終用戶分類 - 全球預測 2025-2030

Cancer Immunotherapy Market by Product (Cell Therapies, Checkpoint Inhibitors, Immunomodulators), Function (Breast Cancer, Colorectal Cancer, Head & Neck Cancer), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年癌症免疫治療市場價值為733.8億美元，預計到2024年將達到773.9億美元，複合年成長率為5.54%，預計到2030年將達到1071.1億美元。

癌症免疫療法是腫瘤學的一個突破性領域，它利用人體的免疫系統來對抗癌細胞，與化療和放射線治療等傳統療法相比，我們提供更有針對性的治療方法。癌症免疫療法的需求在於其延長存活期、提高療效和減少副作用的潛力。癌症免疫療法可應用於多種癌症類型，包括黑色素瘤、肺癌和白血病，並且對於患者特定的治療計劃至關重要。最終用途範圍主要包括醫院、癌症研究中心和專科診所，可以在其中進行和監測這些治療方法。

主要市場統計
基準年[2023] 733.8億美元
預測年份 [2024] 773.9億美元
預測年份 [2030] 1071.1億美元
複合年成長率（%） 5.54%

生物技術的進步、癌症發生率的增加以及個人化醫療意識的增強是市場成長的主要驅動力。主要商機在於新型免疫療法藥物的開發、與現有治療藥物的聯合使用以及拓展醫療基礎設施發達的新興市場。抓住這些機會的研究包括投資於研發、培養與生物技術公司的合作夥伴關係以及在潛力開拓的地區建立市場影響。

然而，它們面臨著治療成本高、監管途徑複雜和潛在副作用等限制的挑戰。此外，新治療方法的臨床試驗和檢驗所需的時間較長也是限制市場的因素。創新對於克服這些障礙至關重要，聯合治療、患者選擇的生物標記研究以及 CAR-T 細胞療法等現成解決方案的開發等領域尤其有前景。

對改進給藥方法和盡量減少免疫相關副作用的研究可能會進一步支持成長。市場動態是動態的，其特點是技術快速進步和競爭壓力。因此，公司需要隨時了解科學突破、監管變化和夥伴關係機會，以保持競爭力並最佳化其在這個變革性產業的成長策略。

市場動態：揭示快速發展的癌症免疫治療市場的關鍵市場洞察

供需的動態交互作用正在改變癌症免疫治療市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球癌症患者數量增加
    • 先進抗癌藥物的採用增加
    • 癌症治療研發活動投資快速增加
  • 市場限制因素
    • 資本集中治療和治療
  • 市場機會
    • 藥物開發過程中生物資訊學工具的廣泛開發
    • 與癌症免疫療法相關的臨床試驗增加
  • 市場挑戰
    • 限制免疫反應的癌症併發症

波特五力：駕馭癌症免疫治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解癌症免疫治療市場的外部影響

外部宏觀環境因素在塑造癌症免疫治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解癌症免疫治療市場的競爭格局

對癌症免疫治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣癌症免疫治療市場供應商的績效評估

FPNV定位矩陣是評估癌症免疫治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了癌症免疫治療市場的成功之路

癌症免疫治療市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球癌症患者的發生率正在上升
      • 擴大先進癌症治療方法的引進
      • 癌症治療研發活動投資快速增加
    • 抑制因素
      • 資本集中治療和程序
    • 機會
      • 藥物開發過程中生物資訊學工具的廣泛開發
      • 癌症免疫治療臨床試驗數量增加
    • 任務
      • 癌症併發症限制免疫反應
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章癌症免疫治療市場：依產品

  • 細胞療法
    • 嵌合體抗原受體T細胞療法
    • 樹突狀細胞
  • 查核點抑制劑
    • 細胞毒性T淋巴球相關蛋白4
    • 程序性死亡 1 和程序性死亡配體 1
  • 免疫調節劑
    • 粒細胞-巨噬細胞集落刺激因子
    • 干擾素
    • 白細胞介素
    • 溶瘤病毒
  • 單株抗體
    • 雙特異性單株抗體
    • 結合單株抗體
    • 裸單株抗體
  • 疫苗
    • 預防性疫苗
    • 治療性疫苗

第7章癌症免疫治療市場：依功能分類

  • 乳癌
  • 大腸直腸癌
  • 頭頸癌
  • 肺癌
  • 惡性黑色素瘤
  • 多發性骨髓瘤
  • 攝護腺癌

第8章癌症免疫治療市場：依最終用戶分類

  • 癌症研究組織
  • 診所
  • 醫院

第9章美洲癌症免疫治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區癌症免疫治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的癌症免疫治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Amgen Inc.
  • AstraZeneca PLC
  • Avid Bioservices, Inc.
  • Bayer AG
  • Bristol-Myers Squibb
  • CH Boehringer Sohn AG & Ko. KG
  • ELI Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GSK PLC
  • Janssen Global Services, LLC
  • Merck & Co., Inc.
  • Novartis International AG
  • OSE Immunotherapeutics SA
  • Pfizer, Inc.
Product Code: MRR-4330CC794A6B

The Cancer Immunotherapy Market was valued at USD 73.38 billion in 2023, expected to reach USD 77.39 billion in 2024, and is projected to grow at a CAGR of 5.54%, to USD 107.11 billion by 2030.

Cancer immunotherapy, a groundbreaking area within oncology, leverages the body's immune system to combat cancer cells, offering a more targeted approach compared to traditional treatments such as chemotherapy and radiation. The necessity for cancer immunotherapy arises from its potential to provide prolonged survival rates, enhanced efficacy, and reduced side effects. Its applications span various cancer types, including melanoma, lung cancer, and leukemia, making it crucial for patient-specific treatment plans. The end-use scope primarily includes hospitals, cancer research centers, and specialty clinics where these therapies can be administered and monitored.

KEY MARKET STATISTICS
Base Year [2023] USD 73.38 billion
Estimated Year [2024] USD 77.39 billion
Forecast Year [2030] USD 107.11 billion
CAGR (%) 5.54%

Market growth is prominently driven by advancements in biotechnology, increasing prevalence of cancer, and rising awareness about personalized medicine. Key opportunities lie in the development of novel immunotherapeutic agents and combinations with existing therapies, as well as the expansion into emerging markets with improved healthcare infrastructures. Recommendations to seize these opportunities include investing in research and development, fostering collaborations with biotech firms, and establishing market presence in regions with untapped potential.

However, limitations such as high treatment costs, complex regulatory pathways, and potential adverse reactions pose challenges. The market is also constrained by the lengthy timeline necessary for clinical trials and validation of new treatments. Innovation can be pivotal in overcoming these barriers, with areas like combination therapies, biomarker research for patient selection, and development of off-the-shelf solutions like CAR-T cell therapy being particularly promising.

Research into improving delivery methods and minimizing immune-related adverse effects would further aid growth. The cancer immunotherapy market is dynamic, marked by rapid technological advances and competitive pressure. Thus, companies must stay abreast of scientific breakthroughs, regulatory changes, and partnership opportunities to maintain a competitive edge and optimize growth strategies within this transformative sector.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Immunotherapy Market

The Cancer Immunotherapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of cancer patients worldwide
    • Increasing adoption of advanced cancer therapeutics
    • Surging investments in research and development activities of cancer treatment
  • Market Restraints
    • Capital intensive treatment and procedures
  • Market Opportunities
    • Extensive development of bioinformatics tools in drug development process
    • Growing number of clinical trials for cancer immunotherapy
  • Market Challenges
    • Complications in cancer limiting the immune response

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Immunotherapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Immunotherapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Immunotherapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Immunotherapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Immunotherapy Market

A detailed market share analysis in the Cancer Immunotherapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Immunotherapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Immunotherapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Immunotherapy Market

A strategic analysis of the Cancer Immunotherapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Immunotherapy Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., AstraZeneca PLC, Avid Bioservices, Inc., Bayer AG, Bristol-Myers Squibb, C.H. Boehringer Sohn AG & Ko. KG, ELI Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GSK PLC, Janssen Global Services, LLC, Merck & Co., Inc., Novartis International AG, OSE Immunotherapeutics SA, and Pfizer, Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer Immunotherapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Cell Therapies, Checkpoint Inhibitors, Immunomodulators, Monoclonal Antibodies, and Vaccines. The Cell Therapies is further studied across Chimeric Antigen Receptor T Cell Therapy and Dendritic Cells. The Checkpoint Inhibitors is further studied across Cytotoxic T-Lymphocyte-Associated Protein-4 and Programmed Death 1 & Programmed Death Ligand 1. The Immunomodulators is further studied across Granulocyte-Macrophage Colony-Stimulating Factor, Interferons, Interleukins, and Oncolytic Virus. The Monoclonal Antibodies is further studied across Bispecific Monoclonal Antibodies, Conjugated Monoclonal Antibodies, and Naked Monoclonal Antibodies. The Vaccines is further studied across Prophylactic Vaccines and Therapeutic Vaccines.
  • Based on Function, market is studied across Breast Cancer, Colorectal Cancer, Head & Neck Cancer, Lung Cancer, Melanoma, Multiple Myeloma, and Prostate Cancer.
  • Based on End-User, market is studied across Cancer Research Institutes, Clinics, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer patients worldwide
      • 5.1.1.2. Increasing adoption of advanced cancer therapeutics
      • 5.1.1.3. Surging investments in research and development activities of cancer treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Capital intensive treatment and procedures
    • 5.1.3. Opportunities
      • 5.1.3.1. Extensive development of bioinformatics tools in drug development process
      • 5.1.3.2. Growing number of clinical trials for cancer immunotherapy
    • 5.1.4. Challenges
      • 5.1.4.1. Complications in cancer limiting the immune response
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Immunotherapy Market, by Product

  • 6.1. Introduction
  • 6.2. Cell Therapies
    • 6.2.1. Chimeric Antigen Receptor T Cell Therapy
    • 6.2.2. Dendritic Cells
  • 6.3. Checkpoint Inhibitors
    • 6.3.1. Cytotoxic T-Lymphocyte-Associated Protein-4
    • 6.3.2. Programmed Death 1 & Programmed Death Ligand 1
  • 6.4. Immunomodulators
    • 6.4.1. Granulocyte-Macrophage Colony-Stimulating Factor
    • 6.4.2. Interferons
    • 6.4.3. Interleukins
    • 6.4.4. Oncolytic Virus
  • 6.5. Monoclonal Antibodies
    • 6.5.1. Bispecific Monoclonal Antibodies
    • 6.5.2. Conjugated Monoclonal Antibodies
    • 6.5.3. Naked Monoclonal Antibodies
  • 6.6. Vaccines
    • 6.6.1. Prophylactic Vaccines
    • 6.6.2. Therapeutic Vaccines

7. Cancer Immunotherapy Market, by Function

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Colorectal Cancer
  • 7.4. Head & Neck Cancer
  • 7.5. Lung Cancer
  • 7.6. Melanoma
  • 7.7. Multiple Myeloma
  • 7.8. Prostate Cancer

8. Cancer Immunotherapy Market, by End-User

  • 8.1. Introduction
  • 8.2. Cancer Research Institutes
  • 8.3. Clinics
  • 8.4. Hospitals

9. Americas Cancer Immunotherapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cancer Immunotherapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Immunotherapy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. AstraZeneca PLC
  • 3. Avid Bioservices, Inc.
  • 4. Bayer AG
  • 5. Bristol-Myers Squibb
  • 6. C.H. Boehringer Sohn AG & Ko. KG
  • 7. ELI Lilly and Company
  • 8. F. Hoffmann-La Roche Ltd
  • 9. Gilead Sciences, Inc.
  • 10. GSK PLC
  • 11. Janssen Global Services, LLC
  • 12. Merck & Co., Inc.
  • 13. Novartis International AG
  • 14. OSE Immunotherapeutics SA
  • 15. Pfizer, Inc.

LIST OF FIGURES

  • FIGURE 1. CANCER IMMUNOTHERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER IMMUNOTHERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CANCER IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CANCER IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER IMMUNOTHERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PROGRAMMED DEATH 1 & PROGRAMMED DEATH LIGAND 1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTERLEUKINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BISPECIFIC MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY NAKED MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PROPHYLACTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEAD & NECK CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 131. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 139. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 140. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 147. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 148. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 149. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 156. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 163. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 164. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 165. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 179. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 180. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 181. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 187. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 188. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 189. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 195. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 196. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 197. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 212. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 213. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 214. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 220. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 221. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 222. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 228. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 229. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 230. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 236. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 237. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 238. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 244. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 245. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 246. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 252. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 253. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 254. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 260. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 261. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 262. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 268. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 270. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 276. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 277. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 278. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 284. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 285. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 286. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 292. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 293. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 294. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 300. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 301. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 302. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 308. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 309. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 310. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 314. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 316. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 318. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 322. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 324. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 326. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 329. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 330. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 331. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 332. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 333. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 334. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 335. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 336. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 337. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 338. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 339. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 340. SWE